Advertisement
Advertisement
U.S. markets open in 53 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Graphite Bio, Inc. (GRPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.2600+0.0700 (+3.20%)
At close: 04:00PM EDT
2.3100 +0.05 (+2.21%)
Pre-Market: 07:16AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close2.1900
Open2.2000
Bid2.2000 x 2900
Ask2.3900 x 2200
Day's Range2.1900 - 2.3600
52 Week Range2.0700 - 34.0000
Volume379,050
Avg. Volume554,285
Market Cap131.012M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.8500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GRPH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Graphite Bio, Inc.
    Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    17 days agoMorningstar
View more
Advertisement
Advertisement